Wafik El-Deiry: Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Wafik El-Deiry, Director of Legorreta Cancer Center at Brown University, posted on X:
“The system for peer-to-peer appeal of denied pre-authorization in oncology treatment needs urgent attention and reform. I just spent 40 minutes appealing a denial for a younger patient only to get the regimen approved.
Probably half the time was spent discussing the dose of 5-FU in the FOLFOXIRI plus bevacizumab regimen which is 3200 mg/m2 per NEJM and The Lancet Oncology but apparently it is 2400 mg/m2 per NCCN template per Dr. Malik of eviCore healthcare.
I never previously had to argue about doses but here we are in 2025.”
“Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer.”
Authors: Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, Domenico Amoroso, Silvana Chiara, Chiara Carlomagno, Corrado Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023